Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .
Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension
- Conditions
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 3
- Registration Number
- NCT01425242
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Hospital Universitario Pedro Ernesto
- Registration Number
- NCT01409408
- Locations
- 🇧🇷
Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil
Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 62
- Registration Number
- NCT01395199
- Locations
- 🇧🇷
Universidade Estadual de Campinas, Campinas, SP, Brazil
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 975
- Registration Number
- NCT01368536
- Locations
- 🇵🇷
Novartis Investigative Site, San Juan, Puerto Rico
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT01365481
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
- Conditions
- Interventions
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 14
- Registration Number
- NCT01354613
- Locations
- 🇺🇸
UW - Madison, Madison, Wisconsin, United States
Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)
- Conditions
- Interventions
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01337674
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2089
- Registration Number
- NCT01316419
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site 51, Jeju, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 54, Chonbuk, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 55, Busan, Korea, Republic of
MK-0954E Study in Participants With Hypertension (MK-0954E-357)
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 327
- Registration Number
- NCT01302691
Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT01264692
- Locations
- 🇷🇸
Clinical Investigative Site 3001, Belgrade, Serbia
🇷🇸Clinical Investigative Site 3004, Belgrade, Serbia
🇷🇸Clinical Investigative Site 3000, Niska Banja, Serbia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.